Furthermore, the targeted inhibition of DNA repair machinery notably using PARP inhibitors (e.g., Niraparib, Veliparib and Olaparib, currently tested with BRCA1/2mut breast, ovarian and prostate cancers 60, 61) could be especially beneficial for treating HPV-positive cancer patients. The gene discussed is PARP1; the disease is prostate carcinoma.